Evaluation on National Biotechnology Policy (NBP) 2005: Towards Achieving 20 Global Companies In NBP Phase III
Requires Subscription or Fee PDF


Bioeconomy Corporation
global company


The purpose of this paper is to discuss on the latest progress of the NBP 2005 through selecting significant performance indicators towards the end of policy tenure, which is nurturing 20 global status companies. The research was carried out through qualitative method using verbatim analysis from Focus Group Discussion (FGD) with lead implementing agencies, Bioeconomy Corporation and also supported by desktop research from the statistics provided and literature review. Through this research, general performances in NBP Phase II were examined, as they will influence the strategies execution in the Phase III. Hence, researcher was exploring the global companies in the context of NBP in term of definition, grooming programs, potential and existing companies, characteristics, niches, and other relevant information related. The findings of this research indicated that NBP Phase II showed significant achievements while general information on the global companies been obtained, mostly in 3 main biotechnology sectors the namely agriculture, healthcare and industrial biotechnology due to non- disclosure agreement with the companies. Therefore, this research is very useful, it could possibly benefit policy makers in the future on policy planning, and intervention in science, technology, and innovation related policy. Finally, originality value from this research will unlock possibility for future study to conduct quantitative survey on the respective companies and also other international benchmarking indicators. However, the study was only based on the FGD session, documents analysis, and information given from ministries and agencies officers.

Requires Subscription or Fee PDF


Amzan, M. C. (2009). Defining the Born Global Firm. Retrieved from http://www.cemi.com.au/sites/all/publications/BaderMazzarolANZAS2009.pdf

Azevedo, G., & Bertrand, H. (1999). From Multinational to Global Companies: Identifying the Dimensions of the Change.

Biocon. (2016). Biocon : Enhancing Global Healthcare.

Dorocki, Slawomir, Bogus, M. (2014). Regional Variety of Biotechnology Development in Asia, 120, 197–212. https://doi.org/10.1016/j.sbspro.2014.02.097

Forbes. (2017). The World’s Biggest Public Companies. Retrieved from https://www.forbes.com/global2000/list/#header:marketValue_sortreverse:true_industry:Pharmaceuticals

Huebsch, Russel, Kokemuller, N. (2017). Global Company Vs. a Multinational Company. Article. Retrieved from http://smallbusiness.chron.com/global-company-vs-multinational-company-35107.html

OECD. (2009). OECD Biotechnology Statistics 2009. Statistics, 103. https://doi.org/10.1787/9789264073937-en

Rabiee, F. (2004). Focus-group interview and data analysis. Proceedings of the Nutrition Society, 63(4), 655–660. https://doi.org/10.1079/PNS2004399

Thompson, V. (2017). What Makes a Company a Multinational Corporation? Retrieved from http://smallbusiness.chron.com/company-multinational-corporation-60186.html

Traoré, B. N., & Ph, D. (2004). Biotechnology Use and Development Survey: Methodology, Issues and Responses Biotechnology Use and Development Survey : Methodology, Issues and Responses.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.